[Congressional Bills 109th Congress]
[From the U.S. Government Publishing Office]
[S. 1930 Introduced in Senate (IS)]
109th CONGRESS
1st Session
S. 1930
To expand the research, prevention, and awareness activities of the
National Institute of Diabetes and Digestive and Kidney Diseases and
the Centers for Disease Control and Prevention with respect to
inflammatory bowel disease.
_______________________________________________________________________
IN THE SENATE OF THE UNITED STATES
October 27, 2005
Mr. Reid (for himself and Mr. Cochran) introduced the following bill;
which was read twice and referred to the Committee on Health,
Education, Labor, and PensionsYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY
_______________________________________________________________________
A BILL
To expand the research, prevention, and awareness activities of the
National Institute of Diabetes and Digestive and Kidney Diseases and
the Centers for Disease Control and Prevention with respect to
inflammatory bowel disease.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Inflammatory Bowel Disease Research
Act''.
SEC. 2. FINDINGS.
The Congress finds as follows:
(1) Crohn's disease and ulcerative colitis are serious
inflammatory diseases of the gastrointestinal tract.
(2) Crohn's disease may occur in any section of the
gastrointestinal tract but is predominately found in the lower
part of the small intestine and the large intestine. Ulcerative
colitis is characterized by inflammation and ulceration of the
innermost lining of the colon. Complete removal of the colon in
patients with ulcerative colitis can potentially alleviate and
cure symptoms.
(3) Because Crohn's disease and ulcerative colitis behave
similarly, they are collectively known as inflammatory bowel
disease. Both diseases present a variety of symptoms, including
severe diarrhea; abdominal pain with cramps; fever; and rectal
bleeding. There is no known cause of inflammatory bowel
disease, or medical cure.
(4) It is estimated that up to 1,400,000 people in the
United States suffer from inflammatory bowel disease, 30
percent of whom are diagnosed during their childhood years.
(5) Children with inflammatory bowel disease miss school
activities because of bloody diarrhea and abdominal pain, and
many adults who had onset of inflammatory bowel disease as
children had delayed puberty and impaired growth and have never
reached their full genetic growth potential.
(6) Inflammatory bowel disease patients are at high risk
for developing colorectal cancer.
(7) The total annual medical costs for inflammatory bowel
disease patients is estimated at more than $2,000,000,000.
SEC. 3. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
DISEASES; INFLAMMATORY BOWEL DISEASE RESEARCH EXPANSION.
(a) In General.--The Director of the National Institute of Diabetes
and Digestive and Kidney Diseases shall expand, intensify, and
coordinate the activities of the Institute with respect to research on
inflammatory bowel disease, with particular emphasis on the following
areas:
(1) Genetic research on susceptibility for inflammatory
bowel disease, including the interaction of genetic and
environmental factors in the development of the disease.
(2) Research targeted to increase knowledge about the
causes and complications of inflammatory bowel disease in
children.
(3) Animal model research on inflammatory bowel disease,
including genetics in animals.
(4) Clinical inflammatory bowel disease research, including
clinical studies and treatment trials.
(5) Expansion of the Institute's Inflammatory Bowel Disease
Centers program with a focus on pediatric research.
(6) Other research initiatives identified by the scientific
document entitled ``Challenges in Inflammatory Bowel Disease''
and the research agenda for pediatric gastroenterology,
hepatology and nutrition entitled ``Chronic Inflammatory Bowel
Disease''.
(b) Authorization of Appropriations.--
(1) In general.--For the purpose of carrying out subsection
(a), there are authorized to be appropriated $75,000,000 for
fiscal year 2006, $85,000,000 for fiscal year 2007, and
$100,000,000 for fiscal year 2008.
(2) Reservation.--Of the amounts authorized to be
appropriated under paragraph (1), not more than 20 percent
shall be reserved for the training of qualified health
professionals in biomedical research focused on inflammatory
bowel disease, including pediatric investigators.
SEC. 4. CENTERS FOR DISEASE CONTROL AND PREVENTION; NATIONAL
INFLAMMATORY BOWEL DISEASE ACTION PLAN.
(a) In General.--
(1) Preparation of plan.--The Director of the Centers for
Disease Control and Prevention, in consultation with the
inflammatory bowel disease community, shall prepare a
comprehensive plan to address the burden of inflammatory bowel
disease in both adult and pediatric populations (which plan
shall be designated by the Director as the ``National
Inflammatory Bowel Disease Action Plan'').
(2) Report to congress.--Not later than 12 months after the
date of the enactment of this Act, the Director of the Centers
for Disease Control and Prevention shall submit the Plan
referred to in paragraph (1) to the Committee on Energy and
Commerce and the Committee on Appropriations in the House of
Representatives and to the Committee on Health, Education,
Labor and Pensions and the Committee on Appropriations in the
Senate.
(b) Content.--
(1) In general.--The National Inflammatory Bowel Disease
Action Plan shall address strategies for determining the true
prevalence of inflammatory bowel disease in the United States,
and the unique demographic characteristics of the patient
community through the expansion of appropriate epidemiological
activities.
(2) Certain requirements.--The Plan referred to in
paragraph (1) shall--
(A) focus on strategies for increasing awareness
about inflammatory bowel disease within the general
public and the health care community in order to
facilitate more timely and accurate diagnoses; and
(B) address mechanisms designed to prevent the
progression of the disease and the development of
complications, such as colorectal cancer, and other
strategies and activities as deemed appropriate.
(c) Authorization of Appropriations.--For the purpose of carrying
out this section, there is authorized to be appropriated such sums as
may be necessary for fiscal year 2006.
<all>